Schneider Matthias, Mosca Marta, Pego-Reigosa José-Maria, Gunnarsson Iva, Maurel Frédérique, Garofano Anna, Perna Alessandra, Porcasi Rolando, Devilliers Hervé
Policlinic of Rheumatology, Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany.
Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy.
Rheumatology (Oxford). 2017 May 1;56(5):818-828. doi: 10.1093/rheumatology/kew492.
The aim was to evaluate the cross-cultural validity of the Lupus Impact Tracker (LIT) in five European countries and to assess its acceptability and feasibility from the patient and physician perspectives.
A prospective, observational, cross-sectional and multicentre validation study was conducted in clinical settings. Before the visit, patients completed LIT, Short Form 36 (SF-36) and care satisfaction questionnaires. During the visit, physicians assessed disease activity [Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI], organ damage [SLICC/ACR damage index (SDI)] and flare occurrence. Cross-cultural validity was assessed using the Differential Item Functioning method.
Five hundred and sixty-nine SLE patients were included by 25 specialists; 91.7% were outpatients and 89.9% female, with mean age 43.5 (13.0) years. Disease profile was as follows: 18.3% experienced flares; mean SELENA-SLEDAI score 3.4 (4.5); mean SDI score 0.8 (1.4); and SF-36 mean physical and mental component summary scores: physical component summary 42.8 (10.8) and mental component summary 43.0 (12.3). Mean LIT score was 34.2 (22.3) (median: 32.5), indicating that lupus moderately impacted patients' daily life. A cultural Differential Item Functioning of negligible magnitude was detected across countries (pseudo- R 2 difference of 0.01-0.04). Differences were observed between LIT scores and Physician Global Assessment, SELENA-SLEDAI, SDI scores = 0 (P < 0.035) and absence of flares (P = 0.004). The LIT showed a strong association with SF-36 physical and social role functioning, vitality, bodily pain and mental health (P < 0.001). The LIT was well accepted by patients and physicians. It was reliable, with Cronbach α coefficients ranging from 0.89 to 0.92 among countries.
The LIT is validated in the five participating European countries. The results show its reliability and cultural invariability across countries. They suggest that LIT can be used in routine clinical practice to evaluate and follow patient-reported outcomes in order to improve patient-physician interaction.
旨在评估狼疮影响追踪器(LIT)在五个欧洲国家的跨文化效度,并从患者和医生的角度评估其可接受性和可行性。
在临床环境中开展了一项前瞻性、观察性、横断面多中心验证研究。就诊前,患者完成LIT、简明健康状况调查问卷(SF-36)和护理满意度问卷。就诊期间,医生评估疾病活动度[狼疮性红斑国家评估中雌激素的安全性(SELENA)-系统性红斑狼疮疾病活动指数(SLEDAI)]、器官损害[系统性红斑狼疮国际协作临床/美国风湿病学会损伤指数(SDI)]和病情复发情况。采用项目功能差异法评估跨文化效度。
25名专科医生纳入了569例系统性红斑狼疮患者;91.7%为门诊患者,89.9%为女性,平均年龄43.5(13.0)岁。疾病概况如下:18.3%经历过病情复发;SELENA-SLEDAI平均评分为3.4(4.5);SDI平均评分为0.8(1.4);SF-36身体和精神成分总结平均分:身体成分总结分为42.8(10.8),精神成分总结分为43.0(12.3)。LIT平均评分为34.2(22.3)(中位数:32.5),表明狼疮对患者日常生活有中度影响。各国检测到的文化项目功能差异程度可忽略不计(伪R²差异为0.01 - 0.04)。LIT评分与医生整体评估、SELENA-SLEDAI、SDI评分=0(P < 0.035)以及无病情复发(P = 0.004)之间存在差异。LIT与SF-36身体和社会角色功能、活力、身体疼痛和心理健康密切相关(P < 0.001)。LIT得到了患者和医生的广泛认可。它具有可靠性,各国的Cronbach α系数在0.89至0.92之间。
LIT在五个参与研究的欧洲国家得到验证。结果显示了其在各国的可靠性和文化不变性。这表明LIT可用于常规临床实践,以评估和跟踪患者报告的结果,从而改善医患互动。